M. Bradley Calobrace, MD Joins ASERF President's Circle

Dr Bradley Calobrace

Plastic surgeon Bradley Calobrace, MD, of Louisville, Kentucky has joined the Aesthetic Surgery Education and Research Foundation’s (ASERF) exclusive President's Circle. The President Circle acknowledges donors who donate $50,000 or more in cash or make a planned gift of $100,000 or more to ASERF.

Dr. Calobrace joined The Aesthetic Society and ASERF in 2006. He is a world-renowned authority on aesthetic breast surgery, and his generous gift will support critical research needed on breast implant devices and breast health. Dr. Calobrace made his charitable commitment amid the COVID-19 pandemic, as the aesthetic industry faces uncertainty and new standards in safety protocol.

"I am honored Dr. Calobrace entrusted ASERF with his generous donation. It is donations like his that have kept our foundation on solid financial ground," said Luis Rios Jr., MD, president of ASERF. "As new challenges surface in aesthetic surgery, ASERF remains a trusted vehicle for investigating issues important to our members and patients. This donation will help ASERF develop meta-analysis tools to study critical breast implant issues."

"For me, there is no better way than to help support the research efforts of ASERF," said Dr. Calobrace. "With so much uncertainty in issues related to breast implant and surgery safety, I believe the best way forward is ongoing support of research that will provide guidance in our daily practices based on good, evidence-based medicine."

Dr. Calobrace serves on ASERF's BIA-ALCL Patient Assistance Fund and Innovative Procedures Committees. He is a member of The Aesthetic Society's Traveling Professor Program, sits on the Informed Consent Task Force, Breast Implant Illness Task Force, Aesthetic Training Committee Task Force and serves as Chair of the BIA-ALCL Task Force. Dr Calobrace is a member of the Aesthetic Surgery Journal editorial board and has published extensively on the subject of aesthetic breast surgery, co-authoring the 10-year clinical FDA trials for Sientra and Mentor. 

More in News